> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Allergan New Dosing for Dalvance
- URL: https://www.fdaweb.com/fda-approves-allergan-new-dosing-for-dalvance/
- Published: 2016-01-21T12:00:00.000Z
- Updated: 2026-09-15T02:29:55.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5134490

> FDA has approved an Allergan supplemental NDA to update the label for Dalvance (dalbavancin) for injection to include a single dose administered as a 30-minute intravenous (IV) infusion for treating acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible Gram-positive bacteria in adults, including infections caused by methicillin-resistant *Staphylococcus aureus*. The company says that Dalvance is the “first and only 30-minute, single-dose treatment option for ABSSSI that delivers a full course of IV therapy, providing an alternative dosing option for physicians.”  
>  
>  
>  
> The submission was based on results from a Phase 3 study, DUR001-303, which compared a single 1,500 mg dose of Dalvance with the two-dose regimen of 1,000 mg followed one week later by 500 mg. Data demonstrated the 1,500 mg single dose achieved its primary endpoint of non-inferiority to the two-dose regimen, the company says.